Group 1: Fundraising Overview - The company raised a total of RMB 4,581,500,000 through its initial public offering, with a net amount of RMB 4,341,379,433.74 after deducting issuance costs [2] - The funds were deposited into a special account for management and were subject to a tripartite supervision agreement with the sponsor and the bank [2][3] Group 2: Fund Allocation and Project Adjustments - The company decided to terminate five research sub-projects and reallocate the unused funds to other ongoing and new sub-projects, including an investment of RMB 10 million to its wholly-owned subsidiary for a new flu vaccine project [3] - A special account was established for the "high-dose flu virus split vaccine" project, adhering to the principle of "special account storage and special fund usage" [4] Group 3: Tripartite Supervision Agreement - The tripartite agreement involves the company, its subsidiary, and the bank, ensuring that the funds are used exclusively for the designated project [5] - The agreement stipulates that any withdrawal exceeding 20% of the net fundraising amount must be reported to the sponsor within five working days [7] Group 4: Share Buyback Progress - The company plans to repurchase shares using between RMB 10 million and RMB 20 million of surplus funds, with a maximum price of RMB 38.00 per share [11] - As of December 31, 2025, the company had repurchased 384,899 shares, accounting for approximately 0.092% of the total share capital, with a total expenditure of RMB 10,789,216.56 [13]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688297 证券简称：中无人机 公告编号：2026-001 中航（成都）无人机系统股份有限公司 关于股份回购进展公告（更正后） 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ■ 一、回购股份的基本情况 中航（成都）无人机系统股份有限公司（以下简称"公司"）于2025年4月25日召开第五届董事会第二十 八次会议，审议通过了《关于以集中竞价交易方式回购公司股份方案的议案》。2025年6月25日，公司 召开2025年第一次临时股东大会，审议通过了《关于以集中竞价交易方式回购公司股份方案的议案》， 同意公司使用自有资金以集中竞价交易方式进行股份回购，回购股份拟用于员工持股计划或股权激励。 回购资金总额不低于人民币10,000万元（含），不超过人民币20,000万元（含），回购价格不超过60.52 元/股，回购股份期限为股东会审议通过本次股份回购方案后12个月。 具体内容详见公司于2025年4月26日在上海证券交易所（www.sse.com.cn）披露的《中 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688068 证券简称：热景生物 公告编号：2026-001 北京热景生物技术股份有限公司 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7号一一回购股份》等相关 规定，公司在实施回购期间，应当在每个月的前3个交易日内公告截至上月末的回购进展情况。现将公 司回购股份的进展情况公告如下：截至2025年12月31日，公司通过股份回购专用证券账户，以集中竞价 交易方式累计回购股份904,054股，占公司总股本92,707,940股的比例为0.98%，回购成交的最高价为 176.79元/股，最低价为145.59元/股，支付的资金总额为人民币149,955,134.73元（不含印花税、交易佣 金等交易费用）。 本次回购股份进展符合法律法规的规定及公司回购股份方案。 三、其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7号一一回购股 份》等相关规定，在回购期限内根据市场情况择机做出回购决策并予以实施，同时根据回购股份事项进 展情况及时履行信息披露义务，敬请广大投资者注意投资风险。 ...

Core Viewpoint - The announcement details the conversion of the company's convertible bonds and the related changes in share capital, highlighting the bond's conversion price and the number of shares issued during the fourth quarter of 2025 [2][8]. Convertible Bond Issuance Overview - The company issued 15,000,000 convertible bonds at a face value of 100 yuan each, totaling 1.5 billion yuan, approved by the China Securities Regulatory Commission on October 25, 2021 [2][3]. - The bonds were listed on the Shenzhen Stock Exchange on November 26, 2021, under the name "帝欧转债" with the code 127047 [3]. Conversion Details - The conversion period for the bonds started on April 29, 2022, and will end on October 24, 2027 [4]. - The initial conversion price was set at 13.53 yuan per share, which was adjusted to 13.33 yuan after a dividend distribution on June 2, 2022 [5][6]. Conversion Price Adjustments - The conversion price was further adjusted to 13.34 yuan on July 21, 2022, following the cancellation of certain restricted stock options [7]. - A significant adjustment was made on November 1, 2024, reducing the conversion price to 5.10 yuan per share, effective from that date [7]. Share Capital Changes - In the fourth quarter of 2025, the company saw a reduction of 70 bonds (amounting to 7,000 yuan) and issued 1,372 new shares as a result of the bond conversion [8]. - As of December 31, 2025, there were 8,436,824 convertible bonds remaining, with a total balance of 843,682,400 yuan [8]. Share Buyback Progress - The company initiated a share buyback plan on July 10, 2024, with a range of 8.5 million to 16.7 million shares at a maximum price of 5.00 yuan per share [14]. - The buyback price cap was later adjusted to 8.40 yuan, extending the buyback period to January 10, 2026 [15]. - By December 31, 2025, the company had repurchased 10,111,107 shares, representing 1.97% of the total share capital, with a total expenditure of approximately 63.32 million yuan [17][22]. Impact of Share Buyback - The buyback utilized both special loans and the company's own funds, ensuring no significant impact on financial stability or operational capabilities [17]. - The repurchased shares will be used for the conversion of the company's convertible bonds, maintaining compliance with relevant regulations [19][22].

Group 1: Share Buyback Announcement - The company has approved a share buyback plan using its own or raised funds through a concentrated bidding method, with a maximum buyback price of RMB 72.08 per share [2][3] - The estimated minimum number of shares to be repurchased is 138,730 shares, while the maximum is 2,774,700 shares, with the actual number to be determined by the completion of the buyback period [2] - As of December 31, 2025, the company has repurchased a total of 1,628,600 shares, accounting for 0.25% of the total share capital, with a total transaction amount of approximately RMB 79.99 million [2] Group 2: Investment in Healthcare Fund - The company has committed RMB 60 million to participate in the establishment of the China Resources (Chengdu) Pharmaceutical Industry Equity Investment Fund, with a total fund size of RMB 1 billion [8][9] - The fund has completed its registration with the Asset Management Association of China and has received the private fund registration certificate as of December 30, 2025 [10] - The fund aims to invest in the health and wellness sector, leveraging the expertise and resources of the fund manager [8]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 广东海大集团股份有限公司（以下简称"公司"）分别于2025年10月28日、2025年11月14日召开了第七届 董事会第四次会议、2025年第四次临时股东会，审议通过了《关于以集中竞价方式回购公司股份方案的 议案》，同意公司以集中竞价交易方式回购公司部分已在境内发行的A股股票，用于依法注销减少注册 资本及实施股权激励计划及/或员工持股计划。具体内容详见公司在指定信息披露媒体《证券时报》 《中国证券报》《上海证券报》《证券日报》和巨潮资讯网披露的《关于以集中竞价方式回购公司股份 方案的公告》《关于以集中竞价方式回购公司股份方案的报告书》，公告编号：2025-055、2025-061。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第9号一一回购股份》等相关 规定，公司应在回购期间每个月的前三个交易日内披露截至上月末的回购进展情况，现将公司回购股份 进展情况公告如下： 一、截至上月末回购股份的进展情况 （2）中国证监会和深圳证券交易所规定的其他情形。 ...

Group 1 - The core point of the article is that Nantong Chaoda Equipment Co., Ltd. has not yet implemented its previously disclosed share repurchase plan as of December 31, 2025 [1][3] Group 2 - The share repurchase plan was approved by the board on October 27, 2025, with a total funding amount between 25 million yuan and 50 million yuan, and a maximum repurchase price of 65.44 yuan per share [2] - The implementation period for the repurchase plan is within 12 months from the board's approval, ending on October 26, 2026 [2] Group 3 - The company will continue to assess market conditions to implement the repurchase plan within the specified timeframe and will fulfill its information disclosure obligations as required by regulations [4]

Group 1 - Victory Energy announced that its stock price increased by 213.97% from December 12 to December 29, 2025, leading to a review of trading fluctuations, with stock resuming trading on January 6, 2026 [2] - Tianqi Materials plans to conduct maintenance on its 150,000-ton liquid lithium hexafluorophosphate production line for 20 to 30 days, ensuring no significant impact on operations [3] - Yingfang Micro is planning to acquire controlling stakes in several companies, leading to a significant asset restructuring, with stock suspension starting January 6, 2026 [4] Group 2 - Weigao Blood Purification intends to acquire 100% of Weigao Purui for 8.511 billion yuan, which will enhance its product offerings in medical packaging [6] - Zhongtian Rocket reported losses in its carbon/carbon thermal field materials business due to intensified competition in the photovoltaic industry, significantly impacting its consolidated financial statements [7] - Fulin Precision plans to invest 6 billion yuan in a project to produce 500,000 tons of high-end lithium iron phosphate for energy storage, alongside additional projects for precursor materials [8] Group 3 - Deyun Co. announced that its actual controller was arrested for illegal public deposit collection, but this will not significantly affect the company's governance or operations [9] - Jushen Co. signed a 1.34 billion USD bauxite transfer agreement, which is expected to positively impact future financial performance [10] - Sanxia New Materials intends to acquire a 40% stake in a subsidiary for 0 yuan, which is classified as a related party transaction [11] Group 4 - Kelun Pharmaceutical plans to repurchase shares worth 50 million to 100 million yuan for employee stock ownership plans, with a maximum price of 35 yuan per share [13] - Juxing Technology expects a net profit increase of 5.00% to 20.00% for 2025, projecting a profit of 2.419 billion to 2.764 billion yuan [15] - China National Materials Technology anticipates a net profit increase of 73.79% to 118.64% for 2025, driven by improved product structure and sales growth [16] Group 5 - Chifeng Gold forecasts a net profit increase of 70% to 81% for 2025, with gold product sales prices rising approximately 49% [17] - Dingtai High-Tech expects a net profit of 410 million to 460 million yuan for 2025, reflecting an 81% to 103% increase due to rising demand in high-end PCB markets [18] - Zhonggang Luoyang announced plans for shareholders to reduce their stakes by up to 1% of total shares [20]

Core Viewpoint - Shandong Guocer Functional Materials Co., Ltd. announced the progress of its share repurchase plan, which has not yet been implemented as of December 31, 2025, and will proceed based on market conditions within the designated timeframe [1][3]. Group 1: Repurchase Plan Overview - The company approved a share repurchase plan on November 6, 2025, intending to use its own and raised funds to repurchase shares through centralized bidding, aimed at employee stock ownership plans or equity incentive plans [2]. - The total amount allocated for the repurchase is set between 100 million yuan (inclusive) and 200 million yuan (inclusive), with a maximum repurchase price of 30 yuan per share (inclusive) [2]. - The implementation period for the repurchase is up to 12 months from the board's approval date, concluding by November 5, 2026, and does not require shareholder meeting approval [2]. Group 2: Current Status and Future Plans - As of the end of December 2025, the company has not executed the share repurchase as per the regulations of the Shenzhen Stock Exchange [3]. - The company plans to continue the repurchase according to market conditions and will fulfill its information disclosure obligations as required [4]. - Market analysts view the implementation of the repurchase plan as a recognition of the company's value, which may provide support for the company's stock price [4].

Core Viewpoint - Wuxi Honghui New Materials Technology Co., Ltd. has announced the progress of its share repurchase plan, confirming compliance with regulatory requirements and the established repurchase scheme [1][3]. Group 1: Repurchase Plan Overview - The company plans to repurchase shares with a budget between 10 million and 20 million yuan, using its own funds for the buyback [2]. - The maximum repurchase price is set at 15.90 yuan per share, which would allow for the repurchase of approximately 628,900 to 1,257,900 shares, representing about 0.34% to 0.69% of the total share capital [2]. Group 2: Compliance and Implementation - As of December 31, 2025, the company has conducted the share repurchase through a dedicated securities account, adhering to the maximum price limit and using self-owned funds [3]. - The company has strictly followed trading restrictions during the repurchase period, ensuring no repurchase occurred during significant events that could impact stock prices or during other restricted periods [4]. Group 3: Future Plans - The company intends to continue the share repurchase plan within the remaining period until March 5, 2026, based on market conditions and funding arrangements [5]. - The company will fulfill its information disclosure obligations as required by regulations, providing monthly updates on the repurchase progress [5].